The role of E26 transformation-specific variant transcription factor 5 in colorectal cancer cell proliferation and cell cycle progression

• Published in: Cell death & disease Vol. 12; no. 5; p. 427
• Main Authors: Peng, Yi, Feng, Haoran, Wang, Changgang, Song, Zijia, Zhang, Yaqi, Liu, Kun, Cheng, Xi, Zhao, Ren
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 30.04.2021; Springer Nature B.V; Nature Publishing Group
• Subjects: 13; 13/1; 13/109; 13/31; 13/51; 13/95; 38/35; 38/39; 38/90; 631/67/1059/2326; 631/67/395; Angiogenesis; Animals; Antibodies; Biochemistry; Biomedical and Life Sciences; Cell Biology; Cell Culture; Cell cycle; Cell Cycle - physiology; Cell growth; Cell Line, Tumor; Cell proliferation; Cell Proliferation - physiology; Chromatin; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - pathology; Crk-Associated Substrate Protein - metabolism; Cyclin-dependent kinase; Cyclin-dependent kinase 2; Cyclin-dependent kinase 4; Cyclin-dependent kinase inhibitor p21; Cyclin-Dependent Kinase Inhibitor p21 - metabolism; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; G1 phase; Genetic transformation; HCT116 Cells; Heterografts; HT29 Cells; Humans; Immunohistochemistry; Immunology; Immunoprecipitation; Life Sciences; Male; Mice; Mice, Nude; Oncogenes; Phosphorylation; S phase; Transcription factors; Transcription Factors - genetics; Transcription Factors - metabolism; Transfection
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-021-03717-5

E26 transformation-specific variant transcription factor 5 (ETV5) contributes to tumor growth and progression and promotes colorectal cancer (CRC) angiogenesis. Previous studies indicate that ETV5 may regulate the cell cycle, but its detailed mechanism remain unclear. Gene Ontology (GO) analysis of RNA-seq data revealed that ETV5 possibly regulates the cell cycle in CRC. Here, in vitro and in vivo experiments were performed to verify that ETV5 promoted tumor progression and influenced cell cycle G1/S transition. Cell cycle PCR array and co-immunoprecipitation (Co-IP) helped identify the p21-CDKs pathway. Chromatin immunoprecipitation (ChIP) and luciferase reporter assays were performed to determine whether ETV5 binds to the p21 promoter. ETV5 and p21 were detected by immunohistochemistry, and the effects of their expression on CRC patients were evaluated. ETV5 upregulation enhanced tumor proliferative capacity and promoted G1 phase transfer to the S phase. ETV5 knockdown slowed the growth of CRC cells and repressed the G1/S transition. We also found p21 as a downstream target of ETV5. p21 knockdown resulted in faster CRC cell growth and in more cells being driven from the G0/1 phase into the S phase. Co-IP experiments showed that p21 banding to CDK2, CDK4, and CDK6 inhibited p130 phosphorylation. Using the ChIP and luciferase reporter assay, we confirmed that ETV5 bound to the p21 promoter and repressed p21 expression. CRC patients with high ETV5 expression and low p21 expression showed the worst prognosis. Finally, by targeting p21 to regulate CDK function, ETV5 also changed drug-sensitivity to palbociclib and dinaciclib. In conclusion, ETV5 promoted cell cycle G1/S transition through transcriptional inhibition of p21, thereby accelerating tumor growth. Moreover, ETV5 changed drug-sensitivity to palbociclib and dinaciclib. Therefore, therapeutic regimens targeting ETV5 may be promising in improving the efficacy of target-CDK treatment in CRC.